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Novel mutations in the thiazide-sensitive NaCl cotransporter
gene in patients with Gitelman syndrome. Gitelman syndrome
(familial hypokalemia-hypomagnesemia syndrome) is an autoso-
mal recessive inherited renal disorder characterized by defective
tubular reabsorption of magnesium and potassium. In this study a
group of 18 unrelated and 2 related Gitelman patients, collected
from six different countries have been screened for mutations in
the human thiazide-sensitive sodium-chloride cotransporter
(SLC12A3) gene. Fourteen novel SLC12A3 mutations are pre-
sented along with six mutations described earlier, and three
neutral polymorphisms. Among the tested patients are two who
carry a total of three heterozygous SLC12A3 mutations. Two-
thirds of the total number of mutant SLC12A3 alleles are amino
acid substitutions. Most SLC12A3 gene mutations, 14 out of a
total of 20, are localized at the intracellular carboxy-terminal
domain of the NCCT protein. The pathogenicity of individual
SLC12A3 mutations is based upon their predicted effect on
SLC12A3 protein, and segregation in family members. Evolution-
ary conservation of substituted amino acid residues and their
frequency in control chromosomes is presented. Identical muta-
tions have been found in Gitelman families from different geo-
graphical origin, suggesting ancient mutations originating from a
common ancestor. As yet, we have not found any evidence for a
possible genotype-phenotype correlation.
Gitelman syndrome (GS; MIM 263800) is an inherited
renal tubular disorder, primarily characterized by hy-
pokalemic metabolic alkalosis in combination with signifi-
cant hypomagnesemia and low urinary calcium [1]. Patients
with this disorder are often asymptomatic, with the excep-
tion of transient periods of weakness and tetany, sometimes
accompanied by abdominal pain, vomiting and fever. The
relatively mild clinical course of GS, with absence of
polyuria and growth retardation, and the late age of onset
usually allows the differentiation from the more severe
hypokalemic tubulopathy, Bartter syndrome (BS; MIM
241200 and MIM 209930) [2, 3]. In addition, magnesium
levels are normal or only slightly decreased in patients with
BS and urinary calcium excretion is either normal (in
classic BS) or largely increased (in the antenatal variant of
BS). GS is clearly inherited as an autosomal recessive trait
and the possibility of autosomal dominant inheritance in
some families with GS, as suggested by Bettinelli et al [4],
was recently dismissed by molecular genetic analysis show-
ing that inheritance in these sort of families is in fact
pseudo-dominant [5, 6].
Both the observation that the electrolyte disturbances in
GS resemble the effects of chronic thiazide administration
[7–9], as well as the results of clearance studies [10, 11]
have pointed to a defect in distal thiazide-sensitive sodium-
chloride transport in GS. This hypothesis has recently been
substantiated by the demonstration that GS results from
presumptive loss of function mutations in the SLC12A3
gene [5, 6, 12], which encodes the thiazide-sensitive sodi-
um-chloride co-transporter (TSC, NCCT) which is located
in the distal convoluted tubule [13].
The SLC12A3 gene belongs to the solute carrier protein
family 12 (SLC12). In mammals, three distinct members
(SLC12A1, SLC12A2 and SLC12A3) of these electroneu-
tral Na-(K)-Cl cotransporters are known to share a com-
mon structure consisting of 12 transmembrane domains
and intracellular amino- and carboxyterminal regions [14].
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In this article, we report the identification of 20
SLC12A3 mutations, including 14 novel mutations, in a
cohort of 20 GS patients from different geographical
origins. The presumptive effect of these mutations on the
function of the NCCT protein is discussed. Our findings
confirm genetic homogeneity in GS and suggest the exis-
tence of several ancient mutations.
METHODS
Gitelman syndrome families
Seven index patients from six families with GS and 13
sporadic cases were collected from Pediatric Nephrology
and adult Nephrology centers in the Netherlands, Ger-
many, France, the United States and Canada. Patients 4, 5,
6, 12, 13, 15, and 20 are familial cases and the rest of the 20
index patients (Table 1) are sporadic cases. The family
from patient 5 has been described in a previous report [5].
The same holds true for patients 12 and 13, who are
affected siblings from a larger pseudodominant GS family.
Patients 6 is the offspring of a consanguineous couple and
has four affected sibs. This is the largest Dutch GS family
known and has been presented in our previous study as well
[5]. The sporadic cases 2, 7, and 10 have been described
before [15]. The parents of patient 2 are first cousins.
Criteria for acceptance of the diagnosis of GS were: normal
or slightly decreased concentrating ability, normal glomer-
ular filtration rate, serum magnesium level less than 0.65
mmol/liter, serum potassium level less than 3.5 mmol/liter,
and hypocalciuria (urinary calcium ,2 mg/kg per day) [16].
Informed consent was obtained from each participating
subject or the parents of the younger children.
Mutation analysis
Genomic DNA was extracted by a salting out procedure
from peripheral blood lymphocytes [17] and used for PCR
amplification of individual exons of the SLC12A3 gene.
Twenty-six pairs of oligonucleotide primers were generated
to amplify all 26 exons according to data obtained from
Simon et al [12], and Mastroianni et al [6]. Exon 1 was
amplified by using GIT024 as forward primer and GIT039
(59-ATAGAGCTCATATGTGGGCAC-39) as reverse
oligo. A different reverse primer was developed for exon 16
as well (GIT156; 59-CAT GCC TGG TCC CCT GTG
CC-39). Polymerase chain reactions (PCR) were performed
in a 30 ml volume containing 100 ng genomic DNA, 50 ng
primers, 5% DMSO, 1.5 ml 8.3 mM dNTPs, and 3 ml 10 3
Taq buffer (100 mM Tris-HCl, pH 8.4, 100 mM (NH4)2SO4,
100 mM KCl, 22.5 mM MgCl2, 0.1% gelatin, 1% Triton
X-100). PCR fragments were labeled by inclusion of 1 mCi
of [a-32P]dCTP in the reaction mixture. Standard PCR
conditions were performed using standard conditions with
an initial denaturation step at 94°C for 5 minutes subse-
quently followed by 30 cycles with denaturation at 94°C for
1 minute, annealing at 60°C for 1 minute, and elongation at
72°C for 1 minute. Single Strand Conformation Polymor-
phism (SSCP) analysis [18] was performed by electrophore-
sis of amplified PCR fragments on 0.5 3 MDE (FMC
BioProducts, Rockland, ME, USA) gels prepared in 0.6 3
TBE (54 mM Tris, 54 mM boric acid, 1.2 mM EDTA, pH 8.3)
at two different electrophoresis conditions at 4°C temper-
ature, one for 16 hours at 6W, and a second for 6 hours at
40W constant power.
The SLC12A3 exons resulting in SSCP shifts, were
Table 1. Biochemical and clinical characteristics of index patients with Gitelman syndrome
Patients Hypomagnesemiaa Hypocalciuriab Hypokalemiac Fatigue
Carpopedal
spasms Joint pains
1 1 1 1 1 2 2
2 1 1 1 2 2 2
3 1 1 1 2 2 2
4 1 1 1 2 2 2
5 1 1 1 2 1 2
6 1 1 1 2 1 2
7 1 ND 1 1 1 2
8 1 1 1 2 2 2
9 1 1 1 2 2 2
10 1 1 1 1 1 1
11 1 ND 1 2 2 2
12 1 1 1 1 1 1
13 1 1 1 1 1 2
14 1 1 1 2 1 1
15 1 1 1 2 2 1
16 1 1 1 2 2 2
17 1 1 1 1 2 2
18 1 1 1 2 1 2
19 1 1 1 2 2 2
20 1 1 1 1 1 2
a Serum magnesium ,0.65 mmol/liter
b Urinary calcium ,2 mg/kg per day
c Serum potassium ,3.5 mmol/liter
ND is not determined.
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reamplified for direct sequence analysis by PCR reactions
with identical oligonucleotides as was used for PCR-SSCP
analysis. Amplified DNA fragments were isolated from
agarose gels, using the “freeze-squeeze” method and sub-
sequently used as template in PCR cycle-sequence reac-
tions in the presence of dye-dideoxy terminators [19].
Reaction conditions were performed according to proto-
cols supplied by the manufacturer (Perkin-Elmer-ABI,
Foster City, CA, USA) and analyzed on an ABI 377
automated DNA sequencer (Perkin-Elmer-AB).
The segregation of mutations has been studied in mem-
bers of the family of patients 6 (this study), 12 and 13 [5].
RESULTS
Clinical and biochemical data
The clinical and biochemical details of the index cases
with GS are shown in Table 1. Four patients complained of
serious joint pains due to chondrocalcinosis. Seven patients
experienced severe fatigue interfering with daily activities.
Eight patients had no symptoms of magnesium or potas-
sium deficiency and GS was diagnosed when electrolyte
measurements were performed for other reasons (abdom-
inal pain, suspected appendicitis, mild fatigue, systematic
preoperative work-up).
Differential diagnosis from BS in all patients was based
on the presence of severe hypomagnesemia, hypocalciuria,
and urinary normal concentrating capacity.
Mutation detection in the SLC12A3 gene
Human genomic DNAs from 13 sporadic Gitelman
patients and 7 familial cases have been screened for
mutations in the SLC12A3 gene by PCR-SSCP analysis of
26 exons that encode the complete coding region. Ampli-
fied DNA fragments resulting in SSCP band shifts were
sequenced. A total of 20 different mutations have been
identified consisting of 15 missense, 2 splice site, 1 deletion,
1 insertion, and 1 nonsense mutation (Table 2). Six of these
mutations have also been found by others [6, 12]; the
remaining 14 are novel molecular variants of the SLC12A3
gene. Remarkably, most SLC12A3 gene mutations, 14 out
of a total of 20, are localized at the intracellular carboxy-
terminal domain of the NCCT protein (Fig. 1 and Table 2).
In our total study group of 20 patients, seven patients
carry homozygous SLC12A3 mutations (numbers 2, 4, 6, 8,
11, 13 and 20; Table 2) and seven are compound heterozy-
gotes (numbers 3, 5, 6, 12, 14, 15 and 19; Table 2 and Fig.
2). Surprisingly, we have identified only one mutant
SLC12A3 allele in 7 out of 20 patients (numbers 1, 7, 9, 10,
16, 17 and 18; Table 2). In one of these 7, a neutral
polymorphism was detected as well (patient 16; Table 2). A
total of three different silent mutations, Thr465Thr,
Ser628Ser, and Ala714Ala (Table 2) was observed in some
of our Gitelman patients. The two latter polymorphisms
appeared to be present in 4 out of 50 and 3 out of 50 control
alleles, respectively (data not shown).
Fifty control chromosomes were tested for the presence
of the 15 missense mutations that have been identified in
our study group. Thirteen of the 15 mutations appeared to
be absent in these control chromosomes. The Arg904Gln
and Arg919Cys mutations were each observed in 1 out of 50
control chromosomes (data not shown).
The SLC12A3 mutations identified in patient 12 and his
relative patient 13 have been presented earlier [5]. Further-
more, patients 5 and 6 from two Dutch families were
previously used for linkage analysis [5]. Patient 5 revealed
three different heterozygous SLC12A3 mutations (Table
2): one pathogenic mutation is the intron 24 splice site
mutation. The second presumed pathogenic mutation is the
Leu215Pro substitution, which was not found in 50 control
chromosomes after PCR-SSCP analysis of exon 5 (data not
shown). In addition, the Leu215 amino acid residue is
conserved in rat and winter flounder NCCT (Table 3). In
contrast, Arg904 is present in the human NCCT protein
only and not conserved through evolution in rat and winter
flounder NCCT proteins (Table 3) and therefore the substi-
tution of this arginine for a glutamic acid residue (the third
mutation found in patient 5) is less likely to be pathogenic. An
additional important argument against pathogenicity of the
Arg904Gln substitution is the fact that this mutation was also
found in 1 out of 50 control chromosomes.
One other patient (no. 12) was found to carry three
different SLC12A3 mutations (Table 2). Patient 12 ap-
peared to carry two missense mutations, Gly741Arg and
Arg919Cys, in addition to a nonsense mutation. The
Gly741 and Arg919 amino acid residues are strongly con-
served through evolution (Table 3). The Gly741Arg muta-
tion has not been identified in 50 control chromosomes, in
contrast to the Arg919Cys mutation, which was observed in
1 out of 50 control chromosomes.
In patient 6 two different missense mutations, a het-
erozygous Ala226Thr and a homozygous Thr649Arg, were
detected (Fig. 3 and Table 2). The parents, who are
consanguineous, are both heterozygous for Thr649Arg
while all affected children are homozygous for Thr649Arg
(Fig. 3 and 4). Neither of these two mutations were
detected in 50 control chromosomes after SSCP analysis of
exon 5 and 16 (data not shown). Since both Ala226 and
Thr649 amino acid residues are strongly conserved in
homologous SLC12A1, SLC12A2 and SLC12A3 proteins
from different species (Table 3), it is difficult to predict
whether both or only one of the amino acid substitutions
contributes to the clinical phenotype in these patients.
The Arg642His mutation found in patient 10 is caused by
a guanine to adenine nucleotide substitution localized at
the most 39 end of exon 15 (Table 2). Because exon-intron
bounderies are part of strongly conserved splice-site con-
sensus sequences [26] we presume that this mutation may
result in aberrant mRNA splicing instead of an amino acid
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substitution. The splice site mutations in intron 18 and
intron 24 (patients 5, 14, and 16) are changing conserved gt
dinucleotide intron sequences that probably affect correct
mRNA splicing. The deletion and insertion mutations
identified in four patients caused a frameshift resulting in
the introduction of a preliminary stop codon and result in
truncated NCCT proteins. Shorter NCCT proteins are also
predicted in patients carrying the Arg968Stop mutation
(Table 2).
A total of six different mutations are found in more than
one Gitelman family: The 2 bp insertion at the nucleotides
260-263 in three families, one from Canada, one from
Germany and one from Italy; Gly741Arg in four families,
one from Germany, two from the Netherlands, and one
from the United States [1]. Arg209Trp is found in four
Gitelman families, one from the United States, one from
Portugal, and two from Italy. The intron 24 splice donor
site mutation is in two families, one from the United States
Table 2. SLC12A3 gene mutations identified in Gitelman patients with Gitelman syndrome
Patient Exon
Mutation at
nucleotide Homo-/heterozygous Predicted effect on protein
Geographical
origin Reference
1. 1 260-263insCC heterozygous frameshift Pro79 Canada Mastroianni et al, 1996 [6]
introducing stop 35 codons
downstream
this study
2. 1 260-263insCC homozygous frameshift Pro79 Germany Mastroianni et al, 1996 [6]
introducing stop 35 codons
downstream
this study
3. 18 2238T3 G heterozygous Leu738Arg Germany this study;
18 2246G3 A heterozygous Gly741Arg Simon et al, 1996 [12]
Lemmink et al, 1996 [19]
4. 5 650C3 T homozygous Arg209Trp Portugal this study;
Mastroianni et al, 1996 [6]
Simon et al, 1996 [12]
5. 5 669T3 C heterozygous Leu215Pro Netherlands this study
23 2736G3 A heterozygous Arg904Gln
24 2881 1 1G3 T heterozygous splice donor site, truncated
SLC12A3 protein
11 1420C3 T homozygous Thr465Thr, neutral
polymorphism
6. 5 701G3 A heterozygous Ala226Thr Netherlands this study
16 1971C3 G homozygous Thr649Arg
7. 6 807G3 A heterozygous Arg261His Germany this study
8. 14 1704C3 A homozygous Pro560His Canada this study
9. 15 1862G3 A heterozygous Gly613Ser Canada this study
10. 15 1950G3 A heterozygous Arg642His Germany this study
or splice donor site
truncated SLC12A3
protein
11. 16 1988C3 T homozygous Arg655Cys Germany this study
12. 18 2246G3 A heterozygous Gly741Arg Netherlands Lemmink et al, 1996 [5]
24 2780C3 T heterozygous Arg919Cys this study
25 2927C3 T heterozygous Arg968Stop
13. 25 2927C3 T homozygous Arg968Stop Netherlands Simon et al, 1996 [12]
14. 18 2246G3 A heterozygous Gly741Arg United
States
this study;
24 2881 1 1G3 T heterozygous splice donor site truncated
SLC12A3 protein
Lemmink et al, 1996 [6]
Simon et al, 1996 [12]
15. 18 2246G3 A heterozygous Gly741Arg Netherlands Lemmink et al, 1996 [6]
25 2927C3 T heterozygous Arg968Stop
16. 18 2310 1 2T3 G heterozygous splice donor site, truncated
SLC12A3 protein
France this study
17 2167C3 T heterozygous Ala714Ala, neutral
polymorphism
17. 19 2327/2328delA heterozygous truncated SLC12A3
protein, frameshift
Phe767 introducing stop
at 6 codons downstream
France this study
18. 22 25743 C heterozygous Leu850Pro Germany Simon et al, 1996 [12]
this study
19. 22 2579C3 T heterozygous Arg852Cys France this study
23 2736G3 A heterozygous Arg904Gln
15 1909G3 A heterozygous Ser628Ser, neutral
polymorphism
20. 24 2780C3 T heterozygous Arg919Cys Netherlands this study;
25 2927C3 T homozygous Arg968Stop Simon et al, 1996 [12]
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Fig. 1. Localization of SLC12A3 mutations on predicted NCCT protein. Predicted protein structure of NCCT protein with intracellular amino- and
carboxy terminal domains [12]. S1-S12 indicate transmembrane domains 1 to 12. Intron 18 and intron 24 donor splice site mutation are not drawn
because they are not part of protein encoding sequences.
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Fig. 2. DNA sequence analysis of two SLC12A3 missense mutations identified in exon 18 from patient 3 (Table 2). Amino acid residues are indicated
and the corresponding codons are underlined. The coding sequence (39 to 59 end) is shown for A, B, and C which are reverse sequences. D shows forward
sequences with coding sequence from 59 to 39 end. Arrows indicate heterozygous nucleotide substitutions (5N). (A) Control sequence with Gly741
codon (GGG) and Leu738 codon (59-CTG-39). (B) Patient 3 with two heterozygous missense mutations (Gly741Arg and Leu738Arg). (C) The mother
carries the heterozygous Gly741Arg substitution, while the father carries the heterozygous Leu738Arg substitution (D).
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and one from the Netherlands; Arg968Stop is in three families
from the Netherlands; and Leu850Pro is found in two fami-
lies, one from Germany, and one from Spain (Table 2).
DISCUSSION
The assumption that Gitelman syndrome is caused by a
defect in the thiazide-sensitive sodium-chloride cotrans-
porter in the renal distal tubule has recently been proven by
the identification of several mutations in the SLC12A3
gene in patients with GS [5, 6, 12]. In the present study the
specific involvement of this cotransporter in the etiology of
this disorder is further substantiated by the finding of 20
mutations, including 14 new mutations, in a cohort of 20
GS patients from different geographical origin.
Fourteen of the 20 mutations identified in this study are
located at the intracellular C-terminal end of the SLC12A3
protein. Although the SLC12A3 mutations reported in
previous studies are distributed throughout the whole
protein [6, 12], our finding is very remarkable, and may
indicate that the carboxy-terminal end represents a hot spot
for mutations. The localization of SLC12A3 gene muta-
tions at the C-terminal domain may have a deleterious
effect on the activity of the NCCT cotransporter. This
domain contains three putative protein kinase phosphory-
lation sites, predicted at Thr908, Ser804, and Ser953 resi-
dues, and one potential phosphorylation site for cAMP-
dependant protein kinase at Ser857 [22].
Although data about phosphorylation of the NCCT
cotransporter are not yet available, it is well known that
protein phosphorylation plays an important role in regulat-
ing activity of many ion transport systems. Thus, it is
conceivable that structural alterations due to SLC12A3
mutations in the C-terminal domain interfere with phos-
phorylation of the NCCT protein and as such with its
regulation. In addition, a protein disulfide isomerase, an
enzyme known to participate in protein folding, has been
identified that interacts with the carboxy-terminal end of
the NCCT protein at the apical membrane of distal tubule
cells [27].
Among the SLC12A3 mutations identified in our GS
cohort are six variants that are likely to have a deleterious
effect on the function of the SLC12A3 protein. Thus, the
nucleotide insertions (patients 1 and 2; Table 2) and
deletion (patient 17) and the nonsense mutation (no. 12,
13, 15, and 20) will cause premature termination of trans-
lation and result in truncated SLC12A3 transporters. Two
different splice donor site mutations (patients 5, 14, and 16)
alter splice site consensus sequences, and will probably lead
to shorter SLC12A3 mRNAs due to exon skipping. Simi-
larly, the guanine to an adenine nucleotide substitution is
likely to affect correct splicing (patient 10; Table 2).
The majority of the mutations detected in GS cohort,
however, are amino acid substitutions. Our data together
with the results of previous studies [5, 6, 12] indicate that 44
out of a total of 66 identified mutant SLC12A3 alleles are
missense mutations. These mutations are inferred to be
pathogenic when they substitute amino acids, which in view
of their conservation through evolution are presumed to be
of functional importance. All but one (Arg904Gln) of the
15 missense mutations detected in our GS cohort are
substitutions of strongly conserved into non-conservative
Table 3. Evolutionary conservation of SLC12A3 amino acid residues substituted in patients with Gitelman syndrome
SLC12A3 amino acid Trp Pro Thr His His Ser His Arg Cys
substitutions: 1 1 1 1 1 1 1 1 1
Arg209 Leu215 Ala226 Arg261 Pro560 Gly613 Arg642 Thr649 Arg655
1 1 1 1 1 1 1 1 1
hSLC12A3: —GTYFLISRSLGPELGGSIGLIFAFANAVG—INDIRIIGVV—SPGWRPSFQYY—KPEVNWGSSVQAG—HIKNYRPQCLVLTGPPNFRPALVD—
rSLC12A3: —.......R.....L..........A....—....R.....—.....P..R..—......G......—.....R......T.....R.....—
flSLC12A3: —.......R.....L..........A...A—....R.V..I—.....P..RF.—..A...G.....S—.V...R......T...CCR.....—
hSLC12A1: —.A.Y...R.....F..........A...A—T...R...SI—.....PAYGI.—..D...G..T..L—.V..FR...I..T.G.MTR...L.—
rSLC12A1: —.A.Y...R.....F........R.A...R—T...R...SI—.....PAYGI.—..D...G..T..L—.V..FR...I..T.G.MTR...L.—
rbSLC12A1: —.A.Y...R.....F..........A...A—T...R...SI—.....PAYGI.—..D...G..T..L—.V..FR...F..T.G.MTR...L.—
shSLC12A2: —.A.Y...R.....F..A.......A...A—MS..R...SV—.....PA.RF.—..D...G..T..L—.V..FR....LMT.A.TSR...LH—
SLC12A3 amino acid Arg Arg Pro Cys Gln Cys
substitutions: 1 1 1 1 1 1
Leu738 Gly741 Leu850 Arg852 Arg904 Arg919
1 1 11 1 1
hSLC12A3: —MKPNILVVGFKKNW—LIPYLLGRKRRWS—INQNPRAEHTK—MIAPFRLNDGF—
rSLC12A3: —.....L..G.....—.....LHR.K..G—...K.QV....—.....R.....—
flSLC12A3: —I...VLLMG...D.—.L...LTRRK..A—.H.P.QPGNVD—SVNR.R.ETNP—
hSLC12A1: —....TL.IGY....—....ILTLRKK.K—..IR.NK.SW.—..E.YR.HESC—
rSLC12A1: —....TL.IGY....—....ILTLRKK.K—..IK.NK.SW.—..E.YR.HESH—
rbSLC12A1: —....TL.IGY..K.—....ILTLRKK.K—..IK.NK.SW.—..E.YR.HESC—
shSLC12A2: —.R..TL.FG...D.—.....LTT.KK.K—M.TK.SKDNIT—..E..R.HEDD—
Amino acid sequence alignment of human thiazide-sensitive cotransporters (hSLC12A3), rat (rSLC12A3), and winter-flounder (flSLC12A3)
thiazide-sensitive cotransporters [12, 20–22] as well as from bumetanide-sensitive cotransporters from human, rat, rabbit, and shark indicated as
hSLC12A1 [23], rSLC12A1 [21], rbSLC12A1 [24], and shSLC12A2 [25], respectively. Points indicate amino acid residues identical to the hSLC12A3
protein sequence.
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amino acids and were not found in 50 control chromo-
somes. Therefore, it is likely that the majority of these
missense mutations are indeed harmful mutations and not
innocuous polymorphisms. However, to definitely prove
that these amino acid substitutions can indeed result in
impairment or loss of NCCT function, studies are under-
way measuring the effect of individual mutations on sodi-
um-chloride transport in a functional expression system, for
example, measuring chloride uptake after microinjection of
normal and mutant SLC12A3 cRNA into Xenopus laevis
oocytes. In two patients (5 and 12; Table 2), three different
mutations instead of two were found. In these patients one
of the three mutations causes truncation of the protein and
the other two are missense mutations, which are also
possible pathogenic variants in two cases (Leu215Pro and
Gly741Arg; Table 2) because they have not been identified
in healthy controls and result in the substitution of an
amino acid that is strongly conserved through evolution.
The presence of the three mutations identified in these
patients needs to be tested in their respective family
Fig. 3. DNA sequence analysis of exon 16 in
control (A), and patient 6 (B). Arrow indicates
C to G nucleotide substitution which results in
a homozygous threonine 649 to arginine amino
acid substitution (Table 2).
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members in order to establish the inheritance of the
respective mutations, and to deduce which of these muta-
tions, or may be all three, contribute to the phenotype. In
this respect the finding of three distinct mutations in the
muscle chloride channel gene CLCN1, all predicted to be
disease-causing mutations, in a single myotonia congenita
family, is interesting [28].
By definition, patients with an autosomal recessive dis-
order should inherit one mutant allele from each parent. In
40% of GS patients from our study cohort, however, we
have identified only one mutant allele. This finding corrob-
orates with two previous studies reporting the detection of
only one mutant allele in 5 out of 12 and 5 out of 11
kindreds, respectively [6, 12]. There are several explana-
tions to justify this failure to identify both mutant alleles in
all GS patients. Firstly, although we have performed SSCP
analysis for each SLC12A3 exon under two different con-
ditions to increase detection sensitivity, it is known that
mutations can be missed by PCR-SSCP analysis. Secondly,
mutations may be present in gene regulating fragments
such as promoter or enhancer segments, intron sequences
or 59 and 39 non-coding regions, which have not yet been
screened for mutations. Thirdly, large heterozygous
SLC12A3 gene deletions will not be identified by mutation
detection techniques based on analysis of individual exons.
Therefore we plan to test Gitelman patients with only one
mutant SLC12A3 allele for large gene rearrangements by
Southern blot analysis or Pulsed Field gel electrophoresis.
Two patients with only one mutant SLC12A3 allele
appeared to carry nothing else but a silent mutation on the
second allele. Recently, a silent fibrillin-1 gene mutation in
a patient with Marfan syndrome has been shown to induce
exon skipping [29]. In the light of this intriguing finding, it
will be interesting to determine whether silent SLC12A3
mutations can affect normal SLC12A3 function as well.
Therefore, the three neutral polymorphisms identified in
our study cohort will be subjected to further investigation.
Functional effects of the so-called “normal” polymor-
phisms have been described for the b-subunit of the
amiloride-sensitive sodium channel involved in Liddle syn-
drome [30] and for tyrosinase enzyme (TYR gene) activity
in ocular albinism [31].
Five of the 20 mutations detected in our study were
present in Gitelman patients from different geographical
origins, indicating that these mutations may be ancient
variants frequently occuring in GS. To determine whether
Fig. 4. PCR-SSCP analysis of exon 16 in control, patient 6 and family members. Pedigree has been drawn with full symbols indicating affected persons,
and open symbols with point are carriers. Arrows A indicate single-stranded DNA fragments in control and arrows B indicate shifted single-stranded
DNA fragments. Carriers (heterozygous Thr649Arg mutation) show both A and B fragments (I-1, I-2, and II-2) while affected persons (homozygous
Thr649Arg) reveal only B fragments (II-1, II-3, II-4, II-5, and II-7).
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these mutations are introduced into the population by a
single founder, its necessary to study the chromosome 16
haplotypes of the patients carrying these identical muta-
tions.
Mastroianni et al have suggested that patients carrying
homozygous frameshift mutations have a more severe
hypokalemia than patients carrying homozygous or com-
pound heterozygous missense mutations, although they did
not show convincing data to substantiate their assumption
[6]. The only patient in our GS cohort with a homozygous
frameshift mutation (patient 2) had a minimum serum
potassium level of 2.23 mmol/liter without treatment,
whereas in patients with homozygous missense mutations,
minimum potassium level of 2.3 mmol/liter (patient 6), 2.5
mmol/liter (patient 4), and 1.6 mmol/liter (patient 11), were
documented. It is clear that our data do not confirm
Mastroianni’s assumption [6]. Nevertheless, it seems im-
possible, as yet, to draw any firm conclusions about possible
genotype-phenotype correlations as the number of patients
with a specific mutation is too low, and potassium levels
were not always measured under standard conditions. In
addition, the impact of individual mutations on the func-
tion of the thiazide-sensitive co-transporter needs to be
determined. This underscores the necessity of functional
analysis of SLC12A3 mutations in an in vitro expression
system.
Our study confirms the genetic homogeneity of Gitelman
syndrome that is in sharp contrast with the molecular
heterogeneity known for Bartter syndrome. As yet, muta-
tions in the genes encoding either the mTAL apical bumet-
anide-sensitive sodium-potassium-chloride cotransporter
(NKCC2) [23], the mTAL luminal, ATP-regulated potas-
sium channel, ROMK (KCNJ1) [32, 33], and the mTAL
basolateral chloride channel (CLCNKB) [34] have been
identified in families with Bartter syndrome. In a subset of
patients with this syndrome, however, these three genes
could be excluded as responsible for causing the disorder,
indicating that at least one still-unidentified gene must be
involved. The differential diagnosis between classical Bar-
tter syndrome and Gitelman syndrome on clinical and
biochemical grounds is sometimes very difficult, if not
impossible. In view of the genetic homogeneity found in GS
and the observation that mutations in the SLC12A3 gene
have been identified in all GS patients screened up to now,
we conclude that the analysis of the SLC12A3 gene may be
regarded as a powerful diagnostic aid, especially in these
difficult cases.
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